ERBB2 and cancer: Despite general familiarity with the influence of anti-HER2/neu immunoglobulin on the viability and vitality of cancer cell populations and it’s application in clinical oncology, there is surprisingly little known about covalent gemcitabine-(anti-HER2/neu) immunochemotherapeutics and their potential to exert selectively “targeted” anti-neoplastic cytotoxicity against chemotherapeutic-resistant mammary adenocarcinoma [22,23].